Bristol-Myers Squibb and Pfizer announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for Eliquis (apixaban), for prophylaxis of deep vein thrombosis (DVT), which ...
July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...
The earliest published study on this topic was a retrospective case–control study by Northup and associates [8] focusing on 113 inpatients with cirrhosis who had newly diagnosed VTE during hospital ...
Venous Thromboembolism (VTE) is common in patients undergoing treatment for brain tumors. American College of Chest Physicians (ACCP) 2004 consensus conference recommends routine use of intermittent ...
The first clinical use of heparin was for chemoprophylaxis in surgical patients. In 1937, Murray and Crafoord published data evaluating surgical patients who received prophylaxis for DVT. 14 Despite ...
Thromboembolism prophylaxis with aspirin is as effective as low-molecular-weight heparin in preventing mortality at 90 days in orthopedic trauma patients with fractures of an extremity, pelvis, or hip ...
Please provide your email address to receive an email when new articles are posted on . The proportion of patients receiving low-dose aspirin increased from 7.65% in 2012 to 55.29% in 2022. A low-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback